Ambrx Biopharma Revenue 2020-2022 | AMAM

Ambrx Biopharma revenue from 2020 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Ambrx Biopharma Annual Revenue
(Millions of US $)
2021 $7
2020 $14
2019 $10
Ambrx Biopharma Quarterly Revenue
(Millions of US $)
2022-06-30
2021-12-31 $7
2021-06-30
2020-12-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.078B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00